These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 3716382)

  • 1. [Clinical research on the hypolipidemic action of a probucol preparation].
    Naumova R; Kerekovska M; Goranov I; Balabanski L
    Vutr Boles; 1986; 25(2):73-7. PubMed ID: 3716382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.
    Atmeh RF; Stewart JM; Boag DE; Packard CJ; Lorimer AR; Shepherd J
    J Lipid Res; 1983 May; 24(5):588-95. PubMed ID: 6875383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)].
    Rouffy J; Chanu B; Bakir R; Goy-Loepper J; Saya C
    Nouv Presse Med; 1980 Oct; 9(40):3014-7. PubMed ID: 7443443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V; Klör HU; Wechsler JG; Ditschuneit H
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.
    Homma Y; Kobayashi T; Yamaguchi H; Sakane H; Ozawa H; Matsuda M; Mikami Y; Mikami Y; Nakamura H
    Artery; 1993; 20(1):1-18. PubMed ID: 8447724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
    Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
    Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Atherosclerosis; 1980 Nov; 37(3):469-74. PubMed ID: 7458992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of probucol on skin cholesterol concentrations in patients with type II hyperlipoproteineamia (author's transl)].
    Beaumont JL; Jacotot B; Buxtorf JC; Meliço-Silvestre AA; Beaumont V
    Nouv Presse Med; 1980 Oct; 9(40):2995-3000. PubMed ID: 7443438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High-density lipoprotein cholesterol and the atherogenic index in patients with different types of hyperlipoproteinemias].
    Apostolov I; Naumova R; Balabanski L; Goranov I
    Vutr Boles; 1983; 22(3):70-4. PubMed ID: 6649586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
    Goranov I; Naumova R; Kerekovska M; Balabanski L
    Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum cholesterol and triglyceride levels in patients with type II hyperlipoproteinemia treated with probucol].
    Markiewicz M; Rymar B; Horubała-Bielak G; Koziara Z
    Wiad Lek; 1984 Oct; 37(19):1489-93. PubMed ID: 6528586
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
    Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
    Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperlipoproteinemia type III with apolipoprotein E phenotype 2/2].
    Engst R
    Hautarzt; 1985 Nov; 36(11):629-34. PubMed ID: 4077508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severe and mild hypercholesterolaemia with probucol and neomycin.
    Miettinen TA; Toivonen I
    Postgrad Med J; 1975; 51(8):suppl 71-5. PubMed ID: 215985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia.
    Dachet C; Jacotot B; Buxtorf JC
    Atherosclerosis; 1985 Dec; 58(1-3):261-8. PubMed ID: 4091882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.